Jeroen A Schouten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1973155/publications.pdf

Version: 2024-02-01

90 5,052 34 68 papers citations h-index g-index

91 91 91 6263 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. Clinical Microbiology and Infection, 2022, 28, 446.e1-446.e7.	6.0	8
2	Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: a narrative review. Clinical Microbiology and Infection, 2022, 28, 362-370.	6.0	4
3	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13
4	Survey of delivery of parenteral antimicrobials in non-inpatient settings across Europe. International Journal of Antimicrobial Agents, 2022, 59, 106559.	2 . 5	5
5	Absence of candidemia in critically ill patients with COVID-19 receiving selective digestive decontamination. Intensive Care Medicine, 2022, 48, 611-612.	8.2	5
6	Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients. Clinical Pharmacokinetics, 2022, 61, 869-879.	3 . 5	4
7	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. Clinical Pharmacokinetics, 2022, 61, 907-918.	3.5	10
8	Why we prescribe antibiotics for too long in the hospital setting: a systematic scoping review. Journal of Antimicrobial Chemotherapy, 2022, 77, 2105-2119.	3.0	5
9	Importance of antimicrobial stewardship in solid organ transplant recipients: An ESCMID perspective. Transplant Infectious Disease, 2022, 24, .	1.7	2
10	SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients. Scientific Reports, 2022, 12, .	3 . 3	3
11	Antimicrobial stewardship in the emergency department: characteristics and evidence for effectiveness of interventions. Clinical Microbiology and Infection, 2021, 27, 204-209.	6.0	30
12	Quality indicators for appropriate antimicrobial therapy in the emergency department: a pragmatic Delphi procedure. Clinical Microbiology and Infection, 2021, 27, 210-214.	6.0	8
13	Quantity Metrics and Proxy Indicators to Estimate the Volume and Appropriateness of Antibiotics Prescribed in French Nursing Homes: A Cross-sectional Observational Study Based on 2018 Reimbursement Data. Clinical Infectious Diseases, 2021, 72, e493-e500.	5.8	3
14	Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clinical Microbiology and Infection, 2021, 27, 61-66.	6.0	147
15	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	4.0	61
16	Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals. International Journal of Antimicrobial Agents, 2021, 57, 106293.	2. 5	1
17	Barriers and Facilitators in Perioperative Antibiotic Prophylaxis: A Mixed-Methods Study in a Small Island Setting. Antibiotics, 2021, 10, 462.	3.7	O
18	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	8.2	49

#	Article	IF	CITATIONS
19	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	8.2	106
20	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respiratory Medicine, the, 2021, 9, 795-802.	10.7	56
21	High unbound flucloxacillin fraction in critically ill patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 3220-3228.	3.0	9
22	Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Critical Care, 2021, 25, 281.	5.8	50
23	Antimicrobial stewardship, therapeutic drug monitoring and infection management in the ICU: results from the international A-TEAMICU survey. Annals of Intensive Care, 2021, 11, 131.	4.6	22
24	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0122921.	3.9	50
25	Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. Med, 2021, 2, 1163-1170.e2.	4.4	31
26	Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns. International Journal of Antimicrobial Agents, 2021, 58, 106409.	2.5	24
27	Selective Decontamination of the Digestive Tract to Prevent Postoperative Pneumonia and Anastomotic Leakage after Esophagectomy: A Retrospective Cohort Study. Antibiotics, 2021, 10, 43.	3.7	4
28	Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	4.3	82
29	Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure. Clinical Infectious Diseases, 2020, 70, 1075-1082.	5.8	21
30	Management of infected pancreatic necrosis in the intensive care unit: a narrative review. Clinical Microbiology and Infection, 2020, 26, 18-25.	6.0	27
31	Infection prevention practices in the Netherlands: results from a National Survey. Antimicrobial Resistance and Infection Control, 2020, 9, 7.	4.1	4
32	A microbiologist consultant should attend daily ICU rounds. Intensive Care Medicine, 2020, 46, 372-374.	8.2	5
33	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020. 46. 245-265.	8.2	97
34	Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?. Critical Care, 2020, 24, 600.	5.8	51
35	Proxy indicators to estimate the appropriateness of medications prescribed by paediatricians in infectious diseases: a cross-sectional observational study based on reimbursement data. JAC-Antimicrobial Resistance, 2020, 2, dlaa086.	2.1	1
36	Breath-synchronized electrical stimulation of the expiratory muscles in mechanically ventilated patients: a randomized controlled feasibility study and pooled analysis. Critical Care, 2020, 24, 628.	5.8	9

#	Article	IF	CITATIONS
37	COVID-19: don't neglect antimicrobial stewardship principles!. Clinical Microbiology and Infection, 2020, 26, 808-810.	6.0	275
38	COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. Critical Care, 2020, 24, 263.	5.8	26
39	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	8.2	278
40	Personalised antimicrobial dosing: standing on the shoulders of giants. International Journal of Antimicrobial Agents, 2020, 56, 106062.	2.5	6
41	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	8.2	54
42	Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. Clinical Pharmacology and Therapeutics, 2020, 108, 770-774.	4.7	10
43	Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questionsâ€"a viewpoint of experts. Intensive Care Medicine, 2020, 46, 236-244.	8.2	57
44	Proxy indicators to estimate appropriateness of antibiotic prescriptions by general practitioners: a proof-of-concept cross-sectional study based on reimbursement data, north-eastern France 2017. Eurosurveillance, 2020, 25, .	7.0	12
45	Development of quality indicators for the management of Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy, 2019, 74, 3344-3351.	3.0	19
46	Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2061-2068.	2.9	15
47	Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey. International Journal of Antimicrobial Agents, 2019, 54, 338-345.	2.5	8
48	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
49	A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial. Intensive Care Medicine, 2019, 45, 647-656.	8.2	31
50	Appropriate empirical antibiotic use in the emergency department: full compliance matters!. JAC-Antimicrobial Resistance, 2019, 1, dlz061.	2.1	6
51	Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action. Clinical Infectious Diseases, 2019, 68, 1952-1959.	5.8	9
52	Use of evidence-based recommendations in an antibiotic care bundle for the intensive care unit. International Journal of Antimicrobial Agents, 2018, 51, 65-70.	2.5	16
53	Quality of outpatient parenteral antimicrobial therapy (OPAT) care from the patient's perspective: a qualitative study. BMJ Open, 2018, 8, e024564.	1.9	20
54	Development of actionable quality indicators and an action implementation toolbox for appropriate antibiotic use at intensive care units: A modified-RAND Delphi study. PLoS ONE, 2018, 13, e0207991.	2.5	22

#	Article	IF	CITATIONS
55	Human resources required for antimicrobial stewardship teams: a Dutch consensus report. Clinical Microbiology and Infection, 2018, 24, 1273-1279.	6.0	24
56	Legal framework of antimicrobial stewardship in hospitals (LEASH): a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) cross-sectional international survey. International Journal of Antimicrobial Agents, 2018, 52, 616-621.	2.5	8
57	Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi50-vi58.	3.0	89
58	Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi30-vi39.	3.0	43
59	Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi40-vi49.	3.0	61
60	Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure. Journal of Antimicrobial Chemotherapy, 2018, 73, vi59-vi66.	3.0	30
61	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clinical Pharmacokinetics, 2017, 56, 1197-1206.	3.5	27
62	Implementing Antimicrobial Stewardship in Critical Care: A Practical Guide. Annual Update in Intensive Care and Emergency Medicine, 2017, , 15-25.	0.2	0
63	What is antimicrobial stewardship?. Clinical Microbiology and Infection, 2017, 23, 793-798.	6.0	447
64	Quality Indicators to Measure Appropriate Antibiotic Use: Some Thoughts on the Black Box. Clinical Infectious Diseases, 2017, 64, 1295-1295.	5.8	4
65	Human resources estimates and funding for antibiotic stewardship teams are urgently needed. Clinical Microbiology and Infection, 2017, 23, 785-787.	6.0	74
66	ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. Journal of Antimicrobial Chemotherapy, 2017, 72, 2910-2914.	3.0	32
67	Improving Antimicrobial Prescribing: Input from Behavioral Strategies and Quality Improvement Methods. , 2017, , 41-53.		0
68	Antimicrobial Stewardship in ICU., 2017, , 193-203.		1
69	Antibiotic Stewardship in the Netherlands. , 2017, , 299-300.		O
70	An electronic trigger tool to optimise intravenous to oral antibiotic switch: a controlled, interrupted time series study. Antimicrobial Resistance and Infection Control, 2017, 6, 81.	4.1	22
71	Monitoring, documenting and reporting the quality of antibiotic use in the Netherlands: a pilot study to establish a national antimicrobial stewardship registry. BMC Infectious Diseases, 2017, 17, 565.	2.9	33
72	Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infectious Diseases, The, 2016, 16, 819-827.	9.1	646

#	Article	IF	Citations
73	De-constructing de-escalation. Clinical Microbiology and Infection, 2016, 22, 958-959.	6.0	9
74	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clinical Pharmacokinetics, 2016, 55, 723-733.	3.5	35
75	Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 847-856.	9.1	526
76	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. Clinical Infectious Diseases, 2016, 62, 1009-1017.	5.8	168
77	Understanding antibiotic stewardship for the critically ill. Intensive Care Medicine, 2016, 42, 2063-2065.	8.2	12
78	Antibiotic research and development: business as usual?. Journal of Antimicrobial Chemotherapy, 2015, 70, 1604-7.	3.0	60
79	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4403-4409.	3.2	48
80	Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. Journal of Antimicrobial Chemotherapy, 2014, 69, 2258-2264.	3.0	23
81	Factors promoting intensive care patients' perception of feeling safe: A systematic review. International Journal of Nursing Studies, 2014, 51, 261-273.	5.6	62
82	Pharmacokinetics of caspofungin in ICU patients. Journal of Antimicrobial Chemotherapy, 2014, 69, 3294-3299.	3.0	61
83	Prevention of ICU delirium and delirium-related outcome with haloperidol: a study protocol for a multicenter randomized controlled trial. Trials, 2013, 14, 400.	1.6	18
84	Development of Quality Indicators for the Antibiotic Treatment of Complicated Urinary Tract Infections: A First Step to Measure and Improve Care. Clinical Infectious Diseases, 2008, 46, 703-711.	5.8	76
85	Tailored Interventions to Improve Antibiotic Use for Lower Respiratory Tract Infections in Hospitals: A Cluster-Randomized, Controlled Trial. Clinical Infectious Diseases, 2007, 44, 931-941.	5.8	68
86	Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Quality and Safety in Health Care, 2007, 16, 143-149.	2.5	95
87	Clinical indicators: development and applications. Netherlands Journal of Medicine, 2007, 65, 15-22.	0.5	82
88	Staphylococcus aureus Carriage Patterns and the Risk of Infections Associated with Continuous Peritoneal Dialysis. Journal of Clinical Microbiology, 2006, 44, 2233-2236.	3.9	72
89	Quality of Antibiotic Use for Lower Respiratory Tract Infections at Hospitals: (How) Can We Measure It?. Clinical Infectious Diseases, 2005, 41, 450-460.	5.8	56
90	Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. Journal of Antimicrobial Chemotherapy, 2005, 56, 575-582.	3.0	46